.INVESTIGATION HIGHLIGHT.06 August 2024.
A sizable randomized controlled trial with cisgender girls highlights the challenges of fidelity to a daily oral preexposure prevention routine and demonstrates that twice-yearly treatment of lenacapavir can maintain reliable HIV prevention amounts over 6 months.